Fig. 1

Patient disposition. *Three patients in the placebo group were not evaluable for safety (n = 151); these patients were excluded from the calculation of the percentage of patients who discontinued. (dagger) Limited to patients whose study discontinuation dates matched their dates of death. (double dagger) Including but not limited to the following: received a different therapy, transitioned to commercial ruxolitinib, and loss of response